
Progression Patterns and Real-World Docetaxel Experience
Vamsidhar Velcheti, MD, explains that the pattern of progression shapes his next-line choice in squamous non-small cell lung cancer.
Vamsidhar Velcheti, MD, explains that the pattern of progression shapes his next-line choice in squamous non-small cell lung cancer. For long-term immunotherapy responders with oligoprogressive disease, he hesitates to stop the checkpoint inhibitor and uses ablative therapy, while primary refractory or rapid progression leads him to docetaxel. Alexander Spira, MD, PhD, FACP, says docetaxel works modestly, offers a similar mechanism after carboplatin and paclitaxel, and carries alopecia, nail changes, fluid retention, and cytopenias. He generally favors about 6 cycles and describes dreading the drug even as it remains the standard comparator. Balazs Halmos, MD, notes docetaxel has been hard to beat, with response rates that appear somewhat higher after immunotherapy, and reserves ramucirumab for aggressive disease such as liver metastases. Dr. Velcheti says control arms have overperformed and cites real-world survival data near 12 months. Dr. Halmos adapts schedules for some patients with weekly taxanes and calls the overall benefit limited.
Related to this article








